Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
出版年份 2021 全文链接
标题
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
作者
关键词
-
出版物
BMC MICROBIOLOGY
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-06
DOI
10.1186/s12866-021-02135-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline
- (2020) Sara E Boyd et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection
- (2020) Jorge Arca-Suárez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A Primer on AmpC Beta-Lactamases: Necessary Knowledge for an Increasingly Multidrug-Resistant World
- (2019) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Comparison of ceftazidime-avibactam and Ceftolozane-Tazobactam in vitro activities when tested against gram-negative Bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)
- (2019) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
- (2019) José-Manuel Ortiz de la Rosa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- The Global Ascendency of OXA-48-Type Carbapenemases
- (2019) Johann D. D. Pitout et al. CLINICAL MICROBIOLOGY REVIEWS
- In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)
- (2019) James A. Karlowsky et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program
- (2019) Dee Shortridge et al. Journal of Global Antimicrobial Resistance
- In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from United States Hospitals and Comparative Activity of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes
- (2018) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli
- (2018) Suzannah M. Schmidt-Malan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Imipenem-Relebactam against Gram-Negative Bacilli from Global ICU and Non-ICU Wards — SMART 2015-2016
- (2018) Sibylle H. Lob et al. Journal of Global Antimicrobial Resistance
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The global epidemiology of carbapenemase-producing Enterobacteriaceae
- (2016) David van Duin et al. Virulence
- Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
- (2015) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals
- (2014) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
- (2014) David J. Farrell et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Current Challenges in Antimicrobial Chemotherapy
- (2010) Carine Bebrone et al. DRUGS
- Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa
- (2009) J.-M. Rodriguez-Martinez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AmpC -Lactamases
- (2009) G. A. Jacoby CLINICAL MICROBIOLOGY REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More